🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Kodiak Sciences Inc. (KOD)
NASDAQ: KOD · Real-Time Price · USD
97.81
+1.01 (1.04%)
At close: Nov 18, 2026, 4:00 PM EST
98.00
+0.19 (0.19%)
After-hours: Nov 18, 2026, 7:30 PM EST
← View all transcripts

UBS Global Biopharma Conference 2026

Nov 17, 2026

Summary

Tarcocimab’s phase III profile supports a BLA filing targeted this year, with potential 2027 approval. KSI-101’s first phase III data are expected before Christmas, and a second pivotal readout is targeted for May/June.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

All right. Well, good morning, everyone. Thank you very much for joining us on our next session. I am Michael Yee, Senior Biotechnology Analyst and Global Head of Biotech Research here at UBS, and very pleased to have the Chief Executive Officer of Kodiak Sciences, Mr. Victor Perlroth, up here with us. Thank you so much. Great to see you, Victor.

Victor Perlroth
CEO, Kodiak Sciences

Thanks, Mike. Good to be here.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

It has been an exciting year for you. I think your stock is up massively this year, as you have put up a lot of positive data earlier this year and then recently too. Lots of phase III data, very de-risked, very exciting time. If all that was not enough, there is a second drug we are going to get data on too. Let us unpack that a little bit. Maybe you could just give us a brief introduction to Kodiak from the standpoint of what your lead drug is and the value proposition of tarcocimab, and walk through what the profile of that drug looks like, particularly against what everybody knows here in Europe and abroad from Roche and Regeneron with high-dose EYLEA. Talk a little bit about your drug and what was so exciting about the results.

Victor Perlroth
CEO, Kodiak Sciences

Yeah. Thanks, Michael. Well, the journey of the anti-VEGF class obviously goes back more than 20 years. Since that time with Lucentis and EYLEA, with the monthly dosing or the every other month dosing, the journey has been about, well, how do we get that efficacy? How do we get that immediacy? At the same time, how do we get a better durability so that we can give fewer doses over time? That has been a holy grail in the sector. 20 years later, starting in maybe 2004, 2005, 2006, nobody was able to do that.

People began to think, "Well, maybe a biologic can't do that, so maybe you need to have something more exotic like a gene therapy or some sort of drug delivery port or some system." We began the journey a number of years ago to try to solve that problem, and it's a very difficult problem. We developed our ABCs or our antibody conjugate technology, and then we've been testing that with tarcocimab in different ways. The framework that I like to think about is this sort of four-quadrant plot where you have the efficacy, immediacy on the Y-axis and the durability on the X. Where you want to be is that upper right quadrant where you have the same efficacy, immediacy as EYLEA and Lucentis, let's say, and you want to have a definitively different kind of durability.

I think when we went into the DAYBREAK study, and we didn't know, well, what could we show, right? We needed to have that efficacy and immediacy of the Lucentis or EYLEA, and we wanted to try to have a better durability. Obviously in the field, Roche did their best attempt, and with Lucentis, then they were able to develop Vabysmo, which didn't really deliver on the scientific concept of the bispecific mechanism with the Ang-2.

The label, I think, says, "No clinical benefit of Ang-2 was shown." Perhaps it did show some incremental durability, or maybe from a variety of different perspectives, it had maybe incrementally better from a variety of perspectives than, say, EYLEA. Regeneron's attempt to solve the problem, to try to get into that upper right quadrant, was to develop higher-dose EYLEA HD. It, again, is fairly incremental vis-à-vis EYLEA. Vabysmo and EYLEA, we kind of term them as Gen 1.5 agents, and they're just definitively not in that upper right quadrant. Going into DAYBREAK, which was, I think, a study design where we brought a lot of conservatism in terms of the study, but also some new ideas about how we should design the study.

We didn't know before the readout, and running these phase III studies in treatment-naive wet AMD against EYLEA, which is a strong comparator, it's very hard to see what's really happening in the study. I think we were quite measured in advance of the readout.

And we're saying, "Well, maybe we could be a little bit more incrementally better than HD and Vabysmo. Maybe our immediacy could be a little weaker maybe than EYLEA, and that still would be good. Maybe we could be on the edge of the upper right quadrant. Maybe that would be very good." And I think obviously we were very surprised. I mean

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

You were in the upper right-hand quadrant.

Victor Perlroth
CEO, Kodiak Sciences

Yeah, we're

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

So, yeah. So, basically, to summarize for investors, if you haven't taken a look at this data, you basically showed the immediacy right on top of the curves of EYLEA. Tell us about your durability.

Victor Perlroth
CEO, Kodiak Sciences

Yeah. The immediacy is either the same or maybe better, both in terms of the OCT and the fluid control, and also the powerful vision coming out of your starting point. At the same time, we did four loading doses, and coming out of that, we brought essentially, initially 48% of the patients to six-month dosing, and through the endpoint, more than half the patients. There is a lot of, I wouldn't really call it trickery, but a lot of different approaches that sponsors take to try to push durability in different ways. It is important when you interpret studies from Regeneron with HD or Roche with Vabysmo to understand, well, how they define durability in the study. We decided because with tarcocimab, let's not use any gimmicks. Let's try to use retreatment approaches that are as close to what the physicians do in their practice.

What the physician does is they take the OCT image of the fluid of the eye, and they just kind of print it out and put it next to the patient. A photographer does that, and then the physician comes in, and then they look, and if they see any fluid there, they are going to treat the patient.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Right.

Victor Perlroth
CEO, Kodiak Sciences

We established a methodology to do that, whether it is AI or whatever you want to call it. It was just designed to provide a consistency across the study, and it was kind of calibrated where it was very close to the sensitivity limit of the machine.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Yeah.

Victor Perlroth
CEO, Kodiak Sciences

If fluid is definitively there, close to the sensitivity limit of the machine, then we would treat the patient.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Basically, you have five-month average dosing, 48 people, what was the number you gave? 48% of people are getting to six months?

Victor Perlroth
CEO, Kodiak Sciences

Yeah. More than half, yes.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

You have at least one-month gain of durability over high-dose EYLEA and all these other things, and I won't even try to cross-talk compare, but it wasn't like, "Oh, you got an extra." But you're using an extra month, and it was using the most stringent retreatment criteria. A lot of these older studies that people are looking at were getting the four months, but they were using retreatment criteria where they had a certain amount of OCT increase. I can't remember. It depends from study to study. Or letters of loss.

Victor Perlroth
CEO, Kodiak Sciences

Or both, usually.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Yeah.

Nobody does that in clinical practice. The retinal specialist looks at it, "Ah, there's a little bit of fluid," immediately redose, and that was the type of criteria.

Victor Perlroth
CEO, Kodiak Sciences

Yeah, what's amazing really is the results.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Most stringent criteria.

Victor Perlroth
CEO, Kodiak Sciences

The results are so strong in the efficacy and the immediacy and the durability, so impressive. We capped the dosing so that the patients couldn't go longer than six months.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Yeah.

Victor Perlroth
CEO, Kodiak Sciences

But, the majority of the patients didn't meet the criteria even at six months.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Yeah.

Victor Perlroth
CEO, Kodiak Sciences

So the durability is probably even stronger in some way, and it's very nice to have a science hypothesis because we know that when you inject our drug in humans, really it's a half-life of 20 days average. But it's quite interesting that it can range from a 10-day half-life in some patients all the way to

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Yeah

Victor Perlroth
CEO, Kodiak Sciences

a 50-day half-life in other patients. So we have really a science-based support for the agent's

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Yeah

Victor Perlroth
CEO, Kodiak Sciences

behavior in the study, and also related to an improvement, let's say, in the formulation that we made where we've mixed some of the free antibody together with the conjugated antibody.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Yeah.

Victor Perlroth
CEO, Kodiak Sciences

That sort of next-generation version of the formulation really delivered the very special results.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

This AMD data was just presented at the major medical conference. Can you talk about maybe a couple of the key takeaways? Obviously, I listened to the webcast and heard Charles Wykoff, we heard David Brown. These are some of the most renowned KOLs

Victor Perlroth
CEO, Kodiak Sciences

Yeah

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

in the country. What were the sort of two or three key takeaways that investors would say, "Wow, wait, what is the peak sales? What is the uptake of this drug going to be?

Victor Perlroth
CEO, Kodiak Sciences

Well, I do think they were pretty clear that they thought the results were a home run and that the molecule itself is a home run, and that it does represent a new class and a new promise for their patients and for all patients.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

I thought they said new standard of care was what they-

Victor Perlroth
CEO, Kodiak Sciences

Yeah, a new standard of care. That would be quite something.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Yeah.

Victor Perlroth
CEO, Kodiak Sciences

So

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

We have some of the biggest KOLs talking about this new standard of care. Where are you then with this program in terms of regulatory filing? What is the status of this program?

Victor Perlroth
CEO, Kodiak Sciences

Yeah, it is quite exciting after the number of years of work. We are compiling the BLA across the three different diseases of wet AMD, diabetic retinopathy, and also retinal vein occlusion. Major areas within the anti-VEGF class. We are on track, I believe, to file the BLA for that this year. That could be approved, I believe, in 2027.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Okay. What are the I would have to check my Roche and Regeneron analyst. I see Matt in the back there. Where are we with peak sales of the class right now? I am just thinking about market share and what the peak sales of this drug could be.

Victor Perlroth
CEO, Kodiak Sciences

Well, I think the EYLEA HD franchise is north of $8 billion , I believe.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Yeah.

Victor Perlroth
CEO, Kodiak Sciences

I think the Vabysmo, Lucentis franchise, Vabysmo, I think, is trending north of $5 billion. People think it is going to go to $7 billion-$8 billion.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Okay.

Victor Perlroth
CEO, Kodiak Sciences

Certainly it is a class in and around $15 billion.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Okay.

Victor Perlroth
CEO, Kodiak Sciences

Yeah.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

$15 billion peak sales consensus for the class. Your product launching in 2027 could take a meaningful share of that, going against some reputable commercial companies.

Victor Perlroth
CEO, Kodiak Sciences

Yeah.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

How are you going to do that? Is Kodiak itself going to go do that? What is the actual message to investors in terms of Kodiak going to go try and launch this product themselves against Regeneron and Roche?

Victor Perlroth
CEO, Kodiak Sciences

Well, obviously it is a great question. We are continuing to build the company. The focus right now is filing the BLA for tarcocimab, reading out the other program that we will talk about, the KSI-101 later this year, and focus on the BLA for that program.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Yeah.

Victor Perlroth
CEO, Kodiak Sciences

I do think pharma commercial or biopharma commercial is under a lot of pressure, a lot of forces. In the U.S., retina is a fairly focused area, so it is credible for a small company-

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Okay

Victor Perlroth
CEO, Kodiak Sciences

I believe, especially with medicines like ours, tarcocimab, and also KSI-101 program. Both of them should be powerfully differentiated in their markets.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Yeah.

Victor Perlroth
CEO, Kodiak Sciences

I think 101 should be a drug that sells itself, I believe. Although Zenkuda, tarcocimab, is selling into a more complicated commercial area, I think our molecule, from the standpoint of our science, our differentiation story, the data that we've generated, I do think that especially the combination of those two provide us something very special to be able to sell in the buy and bill, with attractive pricing and thoughtful-

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Yeah

Victor Perlroth
CEO, Kodiak Sciences

fairly agile commercial capability.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Oh, look, you have Regeneron, you have Roche as a dominant share. Interestingly enough, in the last month, Merck reported some data. They have reiterated their continued interest in this space. They obviously have a Wnt program they have been interested in that was through an acquisition. We will see how that program plays out, but they have had some bullish comments about the space. Yesterday, J&J just announced an acquisition of another company in the space as well. To me, it looks like there are people that continue to be very focused in retinal.

Victor Perlroth
CEO, Kodiak Sciences

Yeah, I think what is special also about Kodiak is our deep capability in discovery and development.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Okay.

Victor Perlroth
CEO, Kodiak Sciences

We also have our co-owned facility for commercial manufacturing.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Right

Victor Perlroth
CEO, Kodiak Sciences

Ursus, that is Swissmedic approved.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Right.

Victor Perlroth
CEO, Kodiak Sciences

So-

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Just yesterday, can you clarify that? Because this is a really important thing that you've been working on the last few years. Where is this manufactured? This has all been scaled up. Can you talk a little bit about that?

Victor Perlroth
CEO, Kodiak Sciences

Yeah, we make our antibodies in the U.S., and we make our conjugates in Switzerland.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Okay.

Victor Perlroth
CEO, Kodiak Sciences

The facility that we use for that is a Kodiak co-owned facility that's dedicated to the manufacturing of our ABCs.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Okay.

Victor Perlroth
CEO, Kodiak Sciences

Can provide whatever commercial supply-

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Right

Victor Perlroth
CEO, Kodiak Sciences

is needed.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

You have your own site. This is not third party. This is your own site that's been-

Victor Perlroth
CEO, Kodiak Sciences

Well, it's co-owned.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Co-owned.

Victor Perlroth
CEO, Kodiak Sciences

We funded-

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Yeah

Victor Perlroth
CEO, Kodiak Sciences

funded the CapEx. We have our team. We are part of the Swissmedic approval team.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Okay.

Okay. All right. The point about this is, and this all just happened over the last 12 months, and quite frankly, the major AMD data was just a couple months ago. This is when the stock went up a lot, and so I just want to refresh, because this was all very new and pretty remarkable that this data came out in AMD. If all that was not enough, that you have a multi-billion dollar drug potentially on your hands, we are all eagerly awaiting data on the second franchise, which is a VEGF IL-6 bispecific, and this is for MESI, and also can be developed for DME and other indications, so we do not want to get too complicated here. But explain what this MESI indication is, and explain what the IL-6 bispecific could do in MESI.

Victor Perlroth
CEO, Kodiak Sciences

Yeah. Well, MESI is macular edema secondary to inflammation.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Okay

Victor Perlroth
CEO, Kodiak Sciences

in the eye, and it really reflects the immune system, sort of an autoimmune attack against the retina and against maybe the barrier of the blood, retinal barrier.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Okay.

Victor Perlroth
CEO, Kodiak Sciences

There's maybe 10 or 50 or 100 different causes of why the body would do that.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Okay.

Victor Perlroth
CEO, Kodiak Sciences

Whether you got a tattoo and then the pigment in your immune system attacks that and it cross-reacts, or maybe you had your appendix removed and you have sort of a post-surgical attack that happens, or whether you have juvenile idiopathic arthritis as a child and the immune attack against the arthritis then cross-reacts against the retina. There's many, many causes, historically, different uveitis specialists together with your systemic rheumatologist might try to discover what that proximal catalyst of this

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Okay

Victor Perlroth
CEO, Kodiak Sciences

was, then they would try to address that. What's amazing about our medicine is it's really a drug that seems to be working very powerfully and very immediately against the ocular pathology from all of these different sources.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Because you have an anti-IL-6?

Victor Perlroth
CEO, Kodiak Sciences

Yes.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Yes.

Victor Perlroth
CEO, Kodiak Sciences

Yeah. The anti-VEGF helps anti-IL-6. Together, it must be some synergistic effect, maybe that we do not totally understand, but the combination of those, it is sort of a 1 + 1 = 7

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Yeah

Victor Perlroth
CEO, Kodiak Sciences

kind of concept, and you see it right away. It is a unifying therapy, and you no longer need to have large teams, and a lot of it is just retina. Retina doctors treat macular edema.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Yeah.

Victor Perlroth
CEO, Kodiak Sciences

Macular edema is just a physical thing that you can see on the OCT. Then they do a lot of that treatment with wet AMD, it is fluid, and they do it with macular edema for diabetes, with DME, they do it in retinal vein occlusion.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Yeah.

Victor Perlroth
CEO, Kodiak Sciences

MESI is, in some way, it is not wet AMD, DME, or RVO, it is macular edema, and you may have inflammation or you may have proximally had some cause that led to the inflammation.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

So-

Victor Perlroth
CEO, Kodiak Sciences

It is kind of actually a fairly large set of patients that is quite surprising.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Now, you put some slides on this, so just for an estimate, you think there is approximately about 200,000 patients in the U.S. that have-

Victor Perlroth
CEO, Kodiak Sciences

Yeah, I think we calculated different epidemiology and stuff, maybe looking at it from different ways to is the initial addressable market, say, around 150,000.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

150. What investors have also learned in the last year or two is that Roche has an anti-IL-6, vamikibart. They have reported and presented phase III data for uveitic macular edema, a similar indication, and they have reported phase III data. Can you explain what we have learned from that, how you feel about your drug compared to vamikibart? Ultimately, once we understand that, we'll talk about your phase III that's coming up. So what do we know about vamikibart? What do you think about that result?

Victor Perlroth
CEO, Kodiak Sciences

Yeah, the Roche drug is an anti-IL-6 antibody alone.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Okay.

Victor Perlroth
CEO, Kodiak Sciences

As a result of that, they've defined their indication in a more narrow way.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Okay.

Victor Perlroth
CEO, Kodiak Sciences

They have more excluded types, and they kind of have a narrow view. The drug was impressive in the phase I/II studies.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Okay.

Victor Perlroth
CEO, Kodiak Sciences

There are currently intraocular injected steroids is how you treat these patients.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Okay.

Victor Perlroth
CEO, Kodiak Sciences

When you do that, a large number of these patients will have a permanent glaucoma that emerges over time, and then that will lead to many different types of surgeries, and it's really the beginning of kind of a downhill spiral for the patients.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Okay.

Victor Perlroth
CEO, Kodiak Sciences

Therefore, their data was impressive, and they also tested that antibody, the IL-6, in DME. But I guess I would say that the antibody maybe has some liabilities, and led to some different types of inflammation at higher doses

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Okay

Victor Perlroth
CEO, Kodiak Sciences

mostly in the DME population.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Okay.

Victor Perlroth
CEO, Kodiak Sciences

They therefore tested the two lowest doses in the kind of MESI equivalent disease in their UME studies.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Okay.

Victor Perlroth
CEO, Kodiak Sciences

They had one successful phase III readout and one failed phase III readout. They have spoken with FDA, and they are going to file on their 0.25 mg, their lowest dose. They filed, and they have a PDUFA, they said, for July of 2027.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Okay. Roche vamikibart filed on a mixed package where they have one positive phase III, and the second phase III, it missed on the high dose. It is technically statistically significant, although I guess it is the lower dose. I do not know if they call that nominal-

Victor Perlroth
CEO, Kodiak Sciences

Right

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

statistically significant, but it was not. They tested the high dose first. I do not know if they split it or how they looked at that. In general, the low dose worked. Now, in that result, which they have filed to the FDA and have a July PDUFA date, they have a primary endpoint where they used three-line gainers, but they also did look at BCVA letter improvement in uveitic macular edema. Your study is in MESI, and your primary endpoint is BCVA letter improvement. What would investors expect in your study? A, I assume you think it is positive, and B, what is positive results compared to what we already have from Roche, which is, I will save everybody the analysis, approximately five to eight letters placebo adjusted? You tell me what you think, but our math says five to eight letters.

So, what is a positive result for Kodiak, and define what you think is going to happen?

Victor Perlroth
CEO, Kodiak Sciences

Well, this year, this will be our third top-line data readout phase III. I think in advance of the first one, I think the GLOW2, we said we thought we were going to have a solid readout, and it was even stronger than we thought.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Okay.

Victor Perlroth
CEO, Kodiak Sciences

In advance of the DAYBREAK readout, to be honest, we were not sure. We were pretty measured. We said it is against a strong active comparator, and it is hard to really see what is happening. We are not sure. We are hopeful. I think in advance of this readout, we are very confident, and we are very optimistic. We think we are looking at something special. The data will be available before Christmas, and it is going to be, I think, very exciting. These are very sick patients. The drug is incredibly powerful, incredibly strong, very immediate and packs a big punch. We're testing a 5 mg dose and a 10 mg dose against placebo, sham, essentially. And we've enriched the patients in the pivotal program design where we have what's called the PEAK study cohort one, and we have PEAK study cohort two. Those are really the

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Yeah

Victor Perlroth
CEO, Kodiak Sciences

very sick patients within this population that really have the ability to have a lot of fluid, and their vision is highly deteriorated, and they have relatively low vision to start with.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Yeah.

Victor Perlroth
CEO, Kodiak Sciences

They have a lot of room to pop in terms of vision gain. And then we have sort of a less sick population that we call PINNACLE, which is more of a safety study concept. And the first readout, yeah, is before Christmas, and then we'll have another readout, let's say, in the May timeframe

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Okay

Victor Perlroth
CEO, Kodiak Sciences

for the two. And I think the primary endpoint is the mean change in vision, and then we pop through that, and I guess I would expect very strong gains. Hopefully, we could be looking at north of 10 letters. Obviously, we don't

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Oh, north of 10 letters.

Victor Perlroth
CEO, Kodiak Sciences

know, but let's see. The most important regulated endpoint really is the three-line gain, the 15-letter gain.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Right.

Victor Perlroth
CEO, Kodiak Sciences

It's more of a responder/non-responder analysis.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Yeah.

Victor Perlroth
CEO, Kodiak Sciences

I think we also have six loading doses once a month and the endpoint at week 24, and we're really giving time for the retina to kind of repair.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Yes

Victor Perlroth
CEO, Kodiak Sciences

to really pop the vision.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Yes

Victor Perlroth
CEO, Kodiak Sciences

in the patient. Versus the vamikibart, obviously, it is very difficult to do the cross-trial type comparisons, but we have seen very, very strong and immediate fluid control, even within the first week.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Yes.

Victor Perlroth
CEO, Kodiak Sciences

Essentially normalizing the retinal architecture. It does not matter what the proximal cause is, as I mentioned earlier.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Yes.

Victor Perlroth
CEO, Kodiak Sciences

I think in one of our presentations from the phase I/II, we even shared every OCT from every patient.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Yes

Victor Perlroth
CEO, Kodiak Sciences

I think at the high dose, at baseline, then like week 16 or something. It is very, very strong, irrespective. I think we are very optimistic about the readout. I think the disease is actually a lot more prevalent. A lot of the enrollment that we have seen is coming out of retina practices, which is exciting, not just the uveitis practices. Once the retina physicians understand what the profile is of MESI, which is macular edema that is not wet AMD, not DME or RVO, then they say, "Oh, well, I have 100 patients waiting for injections today."

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Yeah.

Victor Perlroth
CEO, Kodiak Sciences

They go back and do a little mini chart review. They are finding, "Oh, 20 of these patients are MESI patients." That is why we have been able to enroll, even though we tripled the size of the pivotal program.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Right

Victor Perlroth
CEO, Kodiak Sciences

To make sure that it is going to be successful, we are able to enroll those 900 subjects really at the same rate that we thought we might be enrolling the 300 subjects.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Roche's vamikibart, which is the first positive readout for a similar related indication, uveitic macular edema, showed five to eight letters of BCVA placebo-controlled delta, if everybody can remember that. When we look back at your result, cross-trial in phase I and phase II, you were showing, in a nutshell, 50% better efficacy, cross-trial comparison. But importantly, the biology of it was that you have immediacy of the drying on the OCT, a nd that was actually a key competitive advantage, that there's a biology supporting this result. And that is because you're using an IL-6 with a VEGF bispecific.

Victor Perlroth
CEO, Kodiak Sciences

Right.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

And you think, A, I don't know about the IL-6 and how potent it is versus theirs, but that the VEGF component of it, as a bispecific, could be aiding in drying the eye out. Do you think there's biology and specific engineering that makes your molecule better?

Victor Perlroth
CEO, Kodiak Sciences

I think so.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

and that's why you will do north of-

Victor Perlroth
CEO, Kodiak Sciences

Yeah, it's an attractive. It's a great protein. When you're doing drug development, then when you have a very good material, like a good clay, the Zenkuda product, the tarcocimab, as the new formulation is just incredibly stable, which we're very proud of, and that's fantastic. With the KSI-101 product, the protein is just clearly an amazing drug substance, and very powerful, and it must be that the combination of the two mechanisms in this indication is very powerful. Roche, they had maybe more of a, I guess I would say, a more of a wounded substance that they're working with.

They did the best that they could in their SANDCAT and MEERKAT studies.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Right.

Victor Perlroth
CEO, Kodiak Sciences

They also had a sham rate of response that kind of crept up and destroyed their high dose, and they had sort of an inverted dose response curve, which is, you always wonder when you have an inverted dose response, what is that?

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Right.

Victor Perlroth
CEO, Kodiak Sciences

I think in our case, our 5 mg dose is very strong, and the 10 mg dose also very strong.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Yeah.

Victor Perlroth
CEO, Kodiak Sciences

If you're looking at responder versus non-responder, I think, if you look at the sicker patients in the phase I/II study, sort of what we call the PEAK equivalent population that we're now studying in these two pivotals, that's really the group that had, let's say, north of 50% responder rate.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Right.

Victor Perlroth
CEO, Kodiak Sciences

I think we're hoping that we can replicate that in the phase IIIs, and then to keep our placebo rates quite low, certainly in the single digits.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Right. The three-line gainer numbers was north of 50% in the earlier studies.

Victor Perlroth
CEO, Kodiak Sciences

That is right.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

This is a huge bar, and you should not expect much in the placebo.

Victor Perlroth
CEO, Kodiak Sciences

Correct.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

What about safety?

Victor Perlroth
CEO, Kodiak Sciences

Well, what is nice is in the anti-VEGF area, you really need to have close to pristine safety because EYLEA and Lucentis have very good safety. In the MESI area, these patients, safety is, I would not say it is less important, it is just that these patients have inflammation already. They have a more angry eye to start with. Also, there are no approved therapies other than intraocular steroids that are actually very dangerous over time. So it, the benefit-risk is a very different kind of calculus.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Right.

Victor Perlroth
CEO, Kodiak Sciences

There is nothing there. We are delivering the first biologic for the patients. These patients are very sick and on a very complex trajectory of blindness, and so safety is less relevant in this case.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

What is even the Because I thought about this. I am like, when you deal with AMD, I think we have done it for now 10 or 15 years, we have looked at all these major phase III AMD studies, everyone is worried about things like intraocular inflammation, is what had a lot of problems for a lot of drugs. Remember Beovu? And your drug showed remarkable, tarcocimab, remarkable safety. That was part of why your stock went up 170% that day. With this is in MESI, they are starting with inflammation.

Victor Perlroth
CEO, Kodiak Sciences

Right.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Then, you are administering IL-6, which is an anti-inflammation drug. What side effects or what adverse events would even be notable? None? What is-

Victor Perlroth
CEO, Kodiak Sciences

Yeah, I think what you do not want is what the vamikibart molecule has a little bit of, which is where you have sort of an immune attack against the drug in the eye.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Right.

Victor Perlroth
CEO, Kodiak Sciences

That's not very good, and that could maybe lead to more of a class of blinding inflammation. I think we don't anticipate any of that. As I said, that's really a function of kind of the sequence or the clay of that fundamental drug substance. I think we have a very clean drug substance.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Okay.

Victor Perlroth
CEO, Kodiak Sciences

Yeah. We're looking for very nice safety and very strong efficacy.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Okay.

Victor Perlroth
CEO, Kodiak Sciences

Yeah. We're looking to have that product in a BLA. This is the first pivotal readout. The second pivotal, which is a carbon copy of this,

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Yes

Victor Perlroth
CEO, Kodiak Sciences

that's almost fully enrolled, probably will be fully enrolled certainly this year, and that's a 24-week endpoint. So we'll see top-line data from the second pivotal, let's say, in May, June of this year.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Now, in the last minute or so, if I can recall, Roche is now sort of following the same trajectory because they also started an IL-6 VEGF bispecific. Is that correct? They are trying to do DME. Are you also trying to do DME? I mean, the two points was, one, Roche has now started a sort of a program on a bispecific.

Victor Perlroth
CEO, Kodiak Sciences

Well, I do not know what the progress is of their small-

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

I do not know what is going on there.

Victor Perlroth
CEO, Kodiak Sciences

I believe they are progressing their DutaFab program.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Okay.

Victor Perlroth
CEO, Kodiak Sciences

Which is sort of a, I would say, reasonably highly mutated Fab fragment that is designed to bind two different targets. That is quite small. We are developing the KSI-501 asset, which also had a very nice readout in DAYBREAK, very successful in the wet AMD, and that molecule is being explored in the phase III ALTO study, and that is accelerating well. We are enrolling and randomizing a good number of patients.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Yeah.

Victor Perlroth
CEO, Kodiak Sciences

I think we are ahead, and that is a conjugated ABC with a mix of the free protein and the conjugated protein.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

2026 has been noted as one of the biggest capital-raising years in biotech in the last five years, and yet your stock is up north of 250% this year, and you have not done a financing after two positive phase II readouts. The stock was up 170%. You did not do any financing. Why is that?

Victor Perlroth
CEO, Kodiak Sciences

Well, we did set up a shelf after DAYBREAK, and we set up an ATM. We did a small $70 million-

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Off an ATM.

Victor Perlroth
CEO, Kodiak Sciences

offering off an ATM, like a week or two ago. I think we're looking at our company and saying, "Well, what is the CapEx table evolution?" If you look at a $15 billion biotech or a $25 billion biotech, who are the holders that own 5%-20% of those companies?

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Okay.

Victor Perlroth
CEO, Kodiak Sciences

We're really involved in some education and engagement with those investors.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Okay.

Victor Perlroth
CEO, Kodiak Sciences

We're really thinking about how we evolve our shareholder base to those investors. That was part of the ATM transaction that we did a couple of weeks ago.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Okay.

Victor Perlroth
CEO, Kodiak Sciences

Coming after the PEAK readout later this year, we are looking at doing a more traditional financing that will kind of capitalize Kodiak, say, through the maybe the next 18 months. I think what is important is that at Kodiak, over the many years, we are very disciplined.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Yes.

Victor Perlroth
CEO, Kodiak Sciences

We do not blow out the cap table, and we try not to over-raise.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Right.

Victor Perlroth
CEO, Kodiak Sciences

We try to do things in sort of a metered fashion.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Right

Victor Perlroth
CEO, Kodiak Sciences

Consistent with kind of our operational progress. I think we will try to continue that, and I think that has been good for shareholders.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

It's interesting, back in the spring, in March, when you reported out that day, the stock was up like 50%, and people were like, "Well, how come you're not doing a financing?

Victor Perlroth
CEO, Kodiak Sciences

Yeah.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Now the stock's 110. "Oh, well, how come we haven't done a financing?

Victor Perlroth
CEO, Kodiak Sciences

Right. Just remarkable.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Yeah. We look forward to these results, I guess you said before Christmas.

Victor Perlroth
CEO, Kodiak Sciences

Yeah.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Congratulations on the success, and look forward to continued execution in 2027. Thank you.

Victor Perlroth
CEO, Kodiak Sciences

Perfect. Thanks, Michael.

Michael Yee
Senior Biotechnology Analyst and Global Head of Biotech Research, UBS

Thank you.